Abstraction Health

NAC (N-Acetyl Cysteine)

Amino Acid Derivative

Also known as: NAC · N-acetylcysteine · N-acetyl-L-cysteine

🟡Moderate Evidence 38 expert mentions 20 studies referenced

A precursor to glutathione, the body's primary endogenous antioxidant. Used medically for acetaminophen overdose. Studied for respiratory health, OCD, addiction, and oxidative stress. Regulatory status has varied.

Common forms:capsulepowdereffervescent

How expert claims hold up

19 of 38 claims assessed
8Partial11Insufficient19Pending

8 of 19 assessed claims supported or partially supported by published research

Evidence Summary

PubMed / NCBI·May 2026
All 20 studies
20
Studies
5
RCTs
9
Reviews

NAC (N-Acetyl Cysteine) has a well-established biochemical role as a precursor to glutathione, the body's primary intracellular antioxidant, and a meaningful body of human research exists across several health domains including respiratory disease, reproductive health, psychiatric conditions, and aging. The available evidence base — including meta-analyses, RCTs, and systematic reviews — suggests NAC has genuine utility in specific clinical contexts, but the strength and consistency of evidence varies considerably depending on the application. Many expert claims about NAC's broader benefits currently outpace the available clinical trial data. The most compelling evidence from this review comes from a moderate-quality RCT (PMID 35975308) examining GlyNAC — a combination of glycine and NAC — in older adults, which reported improvements across multiple aging-related biomarkers including glutathione levels, oxidative stress markers, mitochondrial function, inflammation, and physical function. This is notable because it suggests NAC may need to be combined with glycine (also a rate-limiting precursor for glutathione synthesis) to meaningfully raise glutathione levels in older populations. Two meta-analyses rated as strong quality assessed NAC's effects on exercise recovery biomarkers and oxidative stress/immune/muscle damage markers, providing some support for its antioxidant and recovery-related mechanisms in humans. Separate clinical evidence supports NAC's use in COPD exacerbations, polycystic ovary syndrome (PCOS), and as a consideration in psychiatric nutraceutical guidelines, though these come largely from moderate-quality individual trials and expert consensus panels rather than large, definitive RCTs. Several important caveats apply. A number of studies in this review lacked reported population details, sample sizes, and specific key findings, limiting the ability to draw firm conclusions. Some articles included (e.g., studies on neoadjuvant chemotherapy economics and vitamin D in breast cancer) appear to have limited direct relevance to NAC supplementation in healthy or general populations, suggesting the evidence base has notable gaps when it comes to NAC's standalone effects in non-clinical populations. The GlyNAC trial, while promising, studied the glycine-plus-NAC combination — making it difficult to isolate NAC's independent contribution. Long-term safety data, optimal dosing, and efficacy in healthy non-elderly adults remain insufficiently characterized by the studies available here.

Read full evidence summary →

Top studies

The impact of N-acetylcysteine on lactate, biomarkers of oxidative stress, immune response, and muscle damage: A systematic review and meta-analysis.

Journal of cellular and molecular medicine · 2024 · Sadowski M et al.
Meta-Analysis🟢
Key finding

The impact of N-acetylcysteine on lactate, biomarkers of oxidative stress, immune response, and muscle damage: A systematic review and meta-analysis.

Funded by: Ministerstwo Edukacji i Nauki
COI: There were no conflict of interests among authors of this review.
PMID: 39632267DOI: 10.1111/jcmm.70198
View on PubMed

Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2022 · Sarris J et al.
Meta-Analysis🟢
Key finding

Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.

Funded by: Industry (inferred from affiliations)
PMID: 35311615DOI: 10.1080/15622975.2021.2013041
View on PubMed

Expert Mentions

All 38 mentions
Andrew Huberman
Stanford School of Medicine / Huberman Lab· PhD, Neuroscience
Caution / warning

"High doses can cause nausea and GI upset."

Extracted claim

High doses of NAC can cause nausea and GI upset.

Insufficient evidence to assessHigh extraction confidence

None of the 10 provided studies report key findings, populations, or limitations that directly address the side effect profile of high-dose NAC supplementation, including nausea and GI upset. While several studies involve NAC (PMIDs 39108325, 35975308, 36384314, 40421021, 35261035), their extracted data fields are empty, making it impossible to assess whether adverse GI effects were documented or reported. The claim itself is a well-recognized caution found in clinical pharmacology and prescribing literature, but the specific evidence base provided here does not support or contradict it.

Andrew Huberman
Stanford School of Medicine / Huberman Lab· PhD, Neuroscience
Caution / warning

"the FDA briefly attempted to remove NAC from the supplement market after a company tried to patent it as a drug. It's currently still available as a supplement, but this regulatory uncertainty is worth tracking."

Extracted claim

The FDA briefly attempted to remove NAC from the supplement market after a company tried to patent it as a drug, and this regulatory uncertainty is worth tracking.

Not yet assessedHigh extraction confidence

Key findings

  • ·NAC is a well-established biochemical precursor to glutathione; this mechanism is supported by both basic science and the GlyNAC RCT in older adults.
  • ·A randomized trial of GlyNAC (glycine + NAC combined) in older adults reported improvements in oxidative stress, mitochondrial dysfunction, inflammation, and physical function — though effects may require both amino acids together, not NAC alone.
  • ·Meta-analyses suggest NAC may positively affect exercise recovery biomarkers (e.g., oxidative stress markers, lactate, muscle damage indicators), though effect sizes and clinical relevance are unclear from the available data.

Evidence gaps

  • ·Most studies combine NAC with other agents (e.g., glycine, vitamin D) or study specific disease populations, making it difficult to isolate the independent effect of NAC supplementation in healthy adults.
  • ·Long-term human trial data on NAC supplementation — including optimal dosing, duration, and sustained clinical outcomes — are largely absent from the available evidence base.
  • ·Mechanistic claims about NAC breaking cycles of mitochondrial oxidative stress and providing broad anti-inflammatory benefits are biologically plausible but not yet confirmed by large, well-controlled human trials specifically testing NAC alone.